Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Banerjee uses weekly paclitaxel as later-line LGSOC therapy, especially when subacute bowel obstruction makes oral MEK inhibitor absorption risky, and has seen responses. If bevacizumab is not contraindicated, she would pair it with weekly paclitaxel, citing bevacizumab activity reports, and might add pembrolizumab if available.

Related Insights

Banerjee says with a KRAS mutation at progression she would likely choose avutometinib plus defactinib in the US, but for KRAS wild-type disease she would try trametinib or binimetinib first. She considers folate-receptor ADC evidence in LGSOC still anecdotal and reserves mirvetuximab after MEK/RAF therapy.

The positive outcome of the KEYNOTE-B96 trial in platinum-resistant ovarian cancer, in contrast to prior failed immunotherapy trials, is likely attributable to the weekly paclitaxel backbone. This metronomic dosing promotes an immune-active tumor microenvironment, enhancing the efficacy of pembrolizumab.

The decision between new regimens in platinum-resistant ovarian cancer—relicorolant/nab-paclitaxel vs. pembrolizumab/paclitaxel—hinges on the patient's need for bevacizumab. If bevacizumab is required for symptomatic disease, the relicorolant combination is off the table.

The combination of deveracib and pembrolizumab shows remarkably high response rates (over 70%) and a promising 19.3-month median PFS in PD-L1 positive patients. This chemotherapy-free regimen demonstrates substantial activity even in PD-L1 negative patients, suggesting a potential paradigm shift away from chemotherapy for this common mutation.

The success of the KEYNOTE-B96 trial highlights weekly paclitaxel as a uniquely effective partner for immunotherapy in platinum-resistant ovarian cancer. Its metronomic dosing modulates the tumor microenvironment, enhances immunogenicity, and reduces immunosuppression, making it superior to other chemotherapies in this combination.

The presence of heterogeneous resistance mutations, some of which may be below detection limits, suggests a new strategy. Using a potent, broad-spectrum combination therapy upfront in the second-line setting, rather than sequential monotherapies, could eradicate more resistant clones and give patients a better chance at long-term survival or even a cure.

In third-line mCRC, drug selection is heavily guided by a patient's accumulated toxicities. For instance, a patient with bone marrow issues from prior chemotherapy might receive a VEGF inhibitor instead of another chemotherapy agent, prioritizing tolerability and quality of life.

With multiple new effective options in platinum-resistant disease (relacorilant, pembrolizumab, ADCs), the key clinical question is shifting from choosing one superior drug to determining the optimal sequence. Biomarkers can guide initial choices, but sequencing multiple regimens, including re-using weekly paclitaxel backbones, is now a viable strategy.

Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.

Clinicians separate maintenance indications instead of combining agents by default. Bevacizumab is selected for higher-risk biology, such as residual disease or ascites where angiogenesis dominates, whereas low-risk HRD-deficient patients can rely solely on PARP inhibitors to prevent unnecessary toxicity.